To illustrate this, HRMAn was used to systematically analyze the impact of IFNγ treatment on type I and type II Toxoplasma strains in five human cell lines: HeLa (cervical carcinoma epithelial), PMA-differentiated THP-1 (macrophage-like), A549 (lung carcinoma epithelia), HFF (primary fibroblasts), and HUVEC (primary endothelial cells) (Figure 3—figure supplements 1–7). The gene discussed is IFNG; the disease is lung carcinoma.